$3.81
11.19% today
Nasdaq, Dec 02, 10:10 pm CET
ISIN
US23284F1057
Symbol
CTMX

CytomX Therapeutics, Inc. Stock price

$3.81
-0.12 3.05% 1M
+1.30 51.79% 6M
+2.78 269.90% YTD
+2.72 249.54% 1Y
+2.10 122.81% 3Y
-3.61 48.65% 5Y
-18.29 82.76% 10Y
-9.09 70.47% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
-0.48 11.19%
ISIN
US23284F1057
Symbol
CTMX
Industry

Key metrics

Basic
Market capitalization
$726.9m
Enterprise Value
$583.3m
Net debt
positive
Cash
$143.6m
Shares outstanding
165.1m
Valuation (TTM | estimate)
P/E
26.8 | 142.9
P/S
6.4 | 7.6
EV/Sales
5.1 | 6.1
EV/FCF
negative
P/B
6.8
Financial Health
Equity Ratio
-0.4%
Return on Equity
-6,988.8%
ROCE
19.8%
ROIC
-271.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$113.6m | $95.1m
EBITDA
$24.5m | $22.4m
EBIT
$23.2m | $4.7m
Net Income
$28.0m | $5.0m
Free Cash Flow
$-72.4m
Growth (TTM | estimate)
Revenue
-10.3% | -31.2%
EBITDA
187.2% | -16.1%
EBIT
246.4% | -81.1%
Net Income
102.6% | -84.4%
Free Cash Flow
18.5%
Margin (TTM | estimate)
Gross
-
EBITDA
21.6% | 23.6%
EBIT
20.5%
Net
24.7% | 5.2%
Free Cash Flow
-63.7%
More
EPS
$0.2
FCF per Share
$-0.4
Short interest
17.9%
Employees
120
Rev per Employee
$1.2m
Show more

Is CytomX Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

CytomX Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a CytomX Therapeutics, Inc. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a CytomX Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from CytomX Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
114 114
10% 10%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 28 28
12% 12%
25%
- Research and Development Expense 62 62
29% 29%
55%
25 25
187% 187%
22%
- Depreciation and Amortization 1.28 1.28
30% 30%
1%
EBIT (Operating Income) EBIT 23 23
246% 246%
20%
Net Profit 28 28
103% 103%
25%

In millions USD.

Don't miss a Thing! We will send you all news about CytomX Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CytomX Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
7 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in December.
Positive
Seeking Alpha
14 days ago
CytomX Therapeutics (CTMX) is highlighted as a Buy, driven by optimism for its masked antibody probody platform targeting cancer. Lead candidate CX-2051 shows promising phase 1 results in refractory colorectal cancer, with disease control in nearly all patients and confirmed responses. CTMX holds a strong financial position with $34.2 million in cash and $109.4 million in investments, supportin...
Neutral
GlobeNewsWire
19 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025, at 9:00 a.m. GMT.
More CytomX Therapeutics, Inc. News

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Head office United States
CEO Sean McCarthy
Employees 120
Founded 2010
Website cytomx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today